RxDoctor Payments Data

Vaibhav Shah, MD

Neurology · Rockledge, FLNPI 1154508083

Payments from drug & device makers

$116,813in general payments, 2019–2025

Across 55 payments — averaging $2123.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$62K
  • Amgen$19K
  • SK Life Science, Inc.$18K
  • UCB SA$12K
  • Ipsen Pharma SAS$5K
  • Ipsen Biopharmaceuticals, Inc$148
  • plus $210 from 4 others

What the payments were for

  • Consulting fees$3,09516%
  • Travel & lodging$14,93080%
  • Food & beverage$6523%
  • Education$850%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,813 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$759,702
Medicare patients
423
Services billed
27,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$364,314
RebifInterferon Beta-1a/Albumin13$131,716
NeuproRotigotine17$26,513
RytaryCarbidopa/Levodopa11$13,118
UbrelvyUbrogepant13$12,901
Emgality PenGalcanezumab-Gnlm11$11,465
Carbidopa-LevodopaCarbidopa/Levodopa157$7,138
Lacosamide16$6,380
Divalproex Sodium ErDivalproex Sodium17$4,211
Gabapentin199$4,068
Levetiracetam86$3,466
Memantine Hcl98$3,422
Duloxetine Hcl95$3,153
Carbamazepine ErCarbamazepine13$2,276
AmantadineAmantadine Hcl14$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$61,641$364,31414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →